Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Last trade$17.87
Day change-$0.215 (-1.19%)
Day range$17.17 – $18.53
Volume637,004
Market cap$2.90B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.9B
Price / earnings
—
Price / book
3.13×
Price / sales
135.54×
EV / sales
130.98×
EV / EBITDA
-5.39×
Profitability
Earnings per share
-$2.00
Return on assets
-25.49%
Return on equity
-34.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
6.21×
Quick ratio
5.94×
Cash ratio
1.08×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$449.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DNLI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$17.78M
$3.6M
$0
$0
$0
$0
$0
$0
Cost of revenue
$192K
$93K
$0
$0
$0
$0
$0
$0
Gross profit
$17.59M
$3.51M
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$37.49M
$36.28M
$33.51M
$39.46M
$35.48M
$32.27M
$29.35M
$30.06M
Research and development
$106.1M
$97.02M
$103.85M
$97.91M
$101.95M
$102.7M
$116.23M
$99.79M
Total operating expenses
$144.34M
$134.05M
$137.36M
$137.37M
$137.43M
$134.96M
$145.58M
$129.85M
Operating income
-$126.75M
-$130.54M
-$137.36M
-$137.37M
-$137.43M
-$134.96M
-$145.58M
-$129.85M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$70.13M
-$127.55M
-$128.45M
-$128.45M
-$126.9M
-$124.12M
-$132.97M
-$114.69M
Income taxes
$0
$0
$0
$102K
$0
$0
$0
$68K
Net income
$70.13M
-$127.55M
-$128.45M
-$128.55M
-$126.9M
-$124.12M
-$132.97M
-$114.75M
Net income attributable to common shareholders
$65.74M
-$127.55M
-$129.81M
-$128.55M
-$126.74M
-$124.12M
-$132.95M
-$114.75M
EBITDA
-$123.18M
-$126.97M
-$134.51M
-$134.5M
-$134.49M
-$131.92M
-$143.26M
-$127.99M
Basic earnings per share
$0.37
-$0.68
-$0.69
-$0.73
-$0.74
-$0.72
-$0.78
-$0.67
Diluted earnings per share
$0.37
-$0.68
-$0.69
-$0.73
-$0.74
-$0.72
-$0.78
-$0.67
Recent news
Company coverage with links to the original publishers.
Denali Therapeutics (DNLI) shares gained 7.8% after reporting Q3 results that beat expectations, with Avlayah revenues reaching $17.8 million and nearly fivefold growth from the previous quarter. The company expects Q4 revenues between $30-32 million and plans multiple 2027 pipeline readouts including an accelerated approval filing for zafinofusp alfa. Despite strong commercial uptake and $1.01 billion in cash, the stock carries a Zacks Rank #3 (Hold) rating due to pipeline setbacks and the loss of Takeda as a partner.
Denali Therapeutics reported a Q3 loss of $0.64 per share, beating consensus estimates of $0.69 loss, with an earnings surprise of +7.25%. The company posted revenues of $17.78 million, surpassing revenue estimates by 41.88% compared to zero revenues a year ago. The stock has gained 14.2% year-to-date, outperforming the S&P 500's 10.2% gain. Denali holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating.
Denali Therapeutics announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million following FDA approval of AVLAYAH, the first FDA-approved biologic designed to cross the blood-brain barrier. The proceeds will support advancement of Denali's clinical pipeline for lysosomal storage disorders and neurodegenerative diseases. However, the article also notes that Biogen and Denali's Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading to discontinuation of the program.
Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carriers. The drug demonstrated acceptable safety and >90% kinase inhibition but did not slow disease progression.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.